The Challenges of Precision Oncology Drug Development and Implementation

Public Health Genomics

Volumn 18, Issue 6, 2015, Pages 338-348

  Hollingsworth, Simon J ^a   Biankin, Andrew V ^b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Drug development; Healthcare systems; Oncology; Personalised medicine; Precision medicine; Stratified medicine; Targeted drugs

Indexed keywords

MOLECULAR MARKER; SORAFENIB;

ADJUVANT CHEMOTHERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG LEGISLATION; DRUG SCREENING; HEALTH CARE SYSTEM; MOLECULAR PATHOLOGY; ONCOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PREVALENCE; PRIORITY JOURNAL; PUBLIC-PRIVATE PARTNERSHIP; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; STUDY DESIGN; CLINICAL TRIAL (TOPIC); COOPERATION; DRUG APPROVAL; ECONOMICS; HUMAN; MOLECULARLY TARGETED THERAPY; PROCEDURES; TRENDS;

CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; MEDICAL ONCOLOGY; MOLECULAR TARGETED THERAPY; PATIENT SELECTION; PRECISION MEDICINE; PUBLIC-PRIVATE SECTOR PARTNERSHIPS;

EID: 84952876960     PISSN: 16624246     EISSN: 16628063     Source Type: Journal    
DOI: 10.1159/000441557     Document Type: Article

References (46)

1. Green ED, Guyer MS; National Human Genome Research Institute: Charting a course for genomic medicine from base pairs to bedside. Nature 2011; 470: 204-213.
2. Association of the British Pharmaceutical Industry: The Stratification of Disease for Personalised Medicines. London, Association of the British Pharmaceutical Industry, 2014.
3. Academy of Medical Science: Realising the Potential of Stratified Medicine. London, Academy of Medical Science, 2013.
4. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN: Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 2014; 13: 419-431.
5. Tsimberidou A-M, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R: Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative. Clin Cancer Res 2012; 18: 6373-6383.
6. Hollebecque A, Massard C, De Baere T, Auger N, Lacroix L, Koubi-Pick V, Vielh P, Lazar V, Bahleda R, Ngo-Camus M: Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial-interim results (abstract). J Clin Oncol 2013; 31(suppl):2512.
7. Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G: Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther 2012; 11: 2062-2071.
8. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S: The battle trial: personalizing therapy for lung cancer. Cancer Discov 2011; 1: 44-53.
9. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C: Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012; 30: 3242-3249.
10. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME: Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 trial (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2012; 132: 1049-1062.
11. Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S: Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy-results from ACRIN 6657/I-SPY trial. Radiology 2012; 263: 663-672.
12. Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M: Locally advanced breast cancers are more likely to present as interval cancers: results from the I-SPY 1 trial (CALGB 150007/150012, ACRIN 6657, Interspore Trial). Breast Cancer Res Treat 2012; 132: 871-879.
13. Lindsay CR, Shaw E, Walker I, Johnson PW: Lessons for molecular diagnostics in oncology from the Cancer Research UK Stratified Medicine Programme. Expert Rev Mol Diagn 2015; 15: 287-289.
14. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-2388.
15. Jänne PA, Yang JC-H, Kim D-W, Planchard D, Ohe Y, Ramalingam SS, Ahn M-J, Kim S-W, Su W-C, Horn L: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015; 372: 1689-1699.
16. US Food and Drug Administration: Nucleic Acid Based Tests. Silver Spring, US Food and Drug Administration, 2015.
17. US Food and Drug Administration: List of Cleared or Approved Companion Diagnostic Devices (in vitro and Imaging Tools). Silver Spring, US Food and Drug Administration, 2015.
18. US Food and Drug Administration: Drug Approvals and Databases. Silver Spring, US Food and Drug Administration, 2015.
19. European Medicines Agency: Approvals. London, European Medicines Agency, 2015.
20. Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ: Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPACT) trial. Clin Cancer Res 2015; 21: 2029-2037.
21. US National Cancer Institute: NCI-Match (Molecular Analysis for Therapy Choice). Rockville, US National Cancer Institute, 2015.
22. Lung Cancer Master Protocol (Lung-MAP) Clinical Trials: Lung-Map-The Lung Cancer Master Protocol 2013.
23. EORTC: Colorectal Cancer Screening Platform: SPECTAcolor. Brussels, EORTC, 2015.
24. EORTC: Colorectal Cancer Screening Platform: SPECTAlung. Brussels, EORTC, 2015.
25. Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, Salgado R, Aftimos P, Saini K, Sotiriou C: The AURORA initiative for metastatic breast cancer. Br J Cancer 2014; 111: 1881-1887.
26. Peel N: Stratified medicine and the lung cancer 'matrix' trial-part of a cancer care revolution. Cancer Research UK Science Blog, 2014.
27. Pancreatic Cancer Action Network: Know Your Tumor. Manhattan Beach, Pancreatic Cancer Action Network, 2015.
28. FoundationOne: What Is FoundationOne? Cambridge, FoundationOne, 2015.
29. Foundation Medicine: Learn More about Cancer and Available Treatment Options. Cambridge, Foundation Medicine, 2015.
30. Perthera: Personalized Cancer Therapy. McLean, Perthera, 2015.
31. Worldwide Innovative Networking: Worldwide Innovative Networking in Personalised Cancer Medicine. Villejuif, Worldwide Innovative Networking, 2015.
32. Simon R, Roychowdhury S: Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013; 12: 358-369.
33. Waddell N, Pajic M, Patch A-M, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K: Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518: 495-501.
34. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, Schnall-Levin M, White J, Sanford EM, An P: Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023-1031.
35. Dawson S-J, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin S-F, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B: Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 2013; 368: 1199-1209.
36. Douillard J-Y, Ostoros G, Cobo M, Ciuleanu T, Cole R, McWalter G, Walker J, Dearden S, Webster A, Milenkova T: Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014; 9: 1345.
37. Chang DK, Grimmond SM, Evans TJ, Biankin AV: Mining the genomes of exceptional responders. Nat Rev Cancer 2014; 14: 291-292.
38. Lewin J, Siu LL: Cancer genomics: the challenge of drug accessibility. Curr Opin Oncol 2015; 27: 250-257.
39. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S: Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001; 19: 1728-1733.
40. English R, Lebovitz Y, Griffin R: Forum on Drug Discovery, Development, and Translation. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Washington, National Academies Press, 2010.
41. Yap TA, Sandhu SK, Workman P, de Bono JS: Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010; 10: 514-523.
42. Mandrekar SJ, Sargent DJ: Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009; 27: 4027-4034.
43. Printz C: Failure rate: why many cancer drugs don't receive FDA approval, and what can be done about it. Cancer 2015; 121: 1529-1530.
44. Sleijfer S, Bogaerts J, Siu LL: Designing transformative clinical trials in the cancer genome era. J Clin Oncol 2013; 31: 1834-1841.
45. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J: Clinical development success rates for investigational drugs. Nat Biotechnol 2014; 32: 40-51.
46. US Food and Drug Administration: Food and Drug Administration Safety and Innovation Act (FDASIA). Silver Spring, US Food and Drug Administration, 2015.